Motolimod (VTX-2337) is a TLR8 agonist which is able to stimulate production of TNF-α and IL-12 from monocytes and myeloid DCs, and stimulates IFN-γ production from NK cells [110]; motolimod has been tested for dose finding in a clinical trial including patients with advanced solid tumors and lymphoma [111], and is currently being tested in patients with recurrent ovarian cancer, in combination with doxorubicin (NCT01666444). The gene discussed is TNF; the disease is ovarian cancer.